ABclonal Technology accelerates the accuracy and precision of cancer research through our comprehensive catalog of high-quality, personalized reagents and services. Our innovative SMab™ technology, the first antibody discovery platform using single primary B cell ex vivo expansion, has produced PathoQ® for precision pathological immunohistochemistry, ABflo® for superior flow cytometry, and custom antibodies for novel targets. Our quantitative PCR mixes and kits marry cost effectiveness with superior results for your genomic analysis. Our versatile research tools cover targets impacting the study of apoptosis, autophagy, metabolism, metastasis, immune evasion, and more, with the ability to analyze tumor biology at multiple levels. Please visit abclonal.com for product information and quote requests.
Abbexa
Abbexa is a dedicated worldwide supplier of biological tools for the life science, pharmaceutical, and biotechnology sectors. Abbexa provides the scientific community with primary antibodies, secondary antibodies, proteins, ELISA kits and enzymes, as well as other kits and tools designed for use in research. We are committed to providing scientists and researchers with the best customer experience and high quality products. We aim to develop relevant, high quality, tested products for the biomedical research market.
Ab Studio, Inc.
At Antibody Studio, we are redefining how therapeutic antibodies are discovered and engineered. Our team of experienced scientists and innovators combines advanced antibody discovery platforms, cutting-edge protein engineering, and AI-powered design to create high-quality antibodies with speed, precision, and reliability. We partner closely with biotech and pharmaceutical teams to solve complex targets, accelerate research timelines, and deliver candidates ready for downstream development. Whether you need leverage our diverse VHH phage libraries, complex multispecific antibody design and development, or rapid affinity optimization/humanization, we bring deep scientific expertise and a commitment to excellence. Above all, we believe breakthrough therapeutics begin with breakthrough discovery—and we’re here to help you make it happen.
1Cell.Ai
1Cell.Ai, based in Foster City, California, is at the forefront of precision oncology, driving personalized cancer therapy with its innovative multi-omics technologies. Among its key advancements is the breakthrough single cell multi-omics platform, which allows for the comprehensive analysis of individual cancer cells across multiple molecular levels, including genomics, transcriptomics, proteomics, and epigenomics. This technology provides deep insights into tumor heterogeneity, enabling the identification of rare cell populations that may drive metastasis or resistance to therapy, and tailoring treatments to improve patient outcomes. 1Cell.Ai has actively contributed to the scientific community, with numerous publications and presentations at leading oncology conferences such as the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). Their research highlights include the application of AI-enabled technologies in predicting homologous recombination deficiency (HRD) from histopathology images and the use of Circulating Tumor Cells (CTCs) for non-invasive cancer monitoring. These studies, presented in journals like the Journal of Clinical Oncology, underscore the potential of combining advanced diagnostics with artificial intelligence to enhance cancer care. The company’s integrated platforms—OncoIncytes® for multiomic profiling, 1Cell SOLO® for AI-driven single-cell isolation, and iCore™ for data integration—are purpose-built to advance: Antibody-drug conjugate (ADC) development, Translational biomarker programs and Patient stratification in clinical trials. See how 1Cell.Ai can democratize precision cancer monitoring and testing to make cancer testing actionable, accessible, and affordable. Operating from their state-of-the-art laboratory in Foster City, California, 1Cell.Ai adheres to the highest standards of quality, ensuring that their tests provide clinicians with the most reliable and comprehensive data to guide treatment decisions. Through strategic partnerships with academic institutions and industry leaders, 1Cell.Ai continues to push the boundaries of cancer care. Their single cell multi-omics technology, in particular, has been recognized for its potential to revolutionize Next-Gen Translational Research marking a significant advancement in the field of personalized oncology.